Distinct CD8 T cell dynamics associate with response to neoadjuvant cancer immunotherapies.

We leverage a clinical trial (NCT04080804) that compared neoadjuvant anti-PD-1, anti-PD-1+CTLA-4, and anti-PD-1+LAG-3 therapies in head and neck squamous cell carcinoma patients. Anti-PD-1+LAG-3, but not anti-PD-1+CTLA-4, induces widespread TCR sharing among the different transcriptional states, as well as increased TCR diversity in responding patients.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Combination therapies promote higher pathologic response rates versus monotherapy, and major pathologic response is associated with better survival.
• 2 To address whether successful immune checkpoint inhibitor (ICI) regimens act through similar or distinct pathways, we robustly and longitudinally characterize transcriptional and proteomic dynamics of CD8 tumor-infiltrating lymphocytes (TILs) in a clonal manner.
• 3 Anti-PD-1+LAG-3 reprograms CD8 TIL with type-I interferon response and exhaustion gene programs into effector memory and resident memory (T/T).

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: